fda approved glp-1 for weight loss New Pill Foundayo (Orforglipron) Gets Approval Obesity First Glp-1 Weight-Loss Pill Wins
Description
In patients with ASCVD and BMI 30 kg/m, evolocumab was associated with a greater reduction in major adverse cardiovascular events, with a more favorable NNT compared with normal-weight individuals
For many, stopping medication was not a choice
If anything, it should increase slightly to compensate for the metabolic support the medication provided
Should I use my current weight or goal weight to calculate protein
Obesity (Silver Spring) 2023;31:24822492
